T

Tempus AI Inc
NASDAQ:TEM

Watchlist Manager
Tempus AI Inc
NASDAQ:TEM
Watchlist
Price: 34.79 USD -0.34% Market Closed
Market Cap: 5.5B USD
Have any thoughts about
Tempus AI Inc?
Write Note

Tempus AI Inc
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tempus AI Inc
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
T
Tempus AI Inc
NASDAQ:TEM
Current Portion of Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Current Portion of Long-Term Debt
$4.1B
CAGR 3-Years
501%
CAGR 5-Years
44%
CAGR 10-Years
3%
Danaher Corp
NYSE:DHR
Current Portion of Long-Term Debt
$1.2B
CAGR 3-Years
456%
CAGR 5-Years
2%
CAGR 10-Years
33%
Mettler-Toledo International Inc
NYSE:MTD
Current Portion of Long-Term Debt
$185.8m
CAGR 3-Years
51%
CAGR 5-Years
31%
CAGR 10-Years
4%
Agilent Technologies Inc
NYSE:A
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Current Portion of Long-Term Debt
$1.2B
CAGR 3-Years
137%
CAGR 5-Years
66%
CAGR 10-Years
50%
No Stocks Found

Tempus AI Inc
Glance View

Market Cap
5.4B USD
Industry
Life Sciences Tools & Services

Tempus AI Inc. stands at the forefront of the healthcare technology revolution, focusing its expertise on the convergence of artificial intelligence and big data to transform the way doctors approach precision medicine. Founded by Eric Lefkofsky in 2015, the company’s mission is to harness the power of data, equipping physicians with crucial insights that can propel patient care forward. With its sprawling genomic database, Tempus aggregates clinical and molecular information, which is then meticulously analyzed to provide actionable insights. Physicians receive comprehensive reports, offering tailored therapeutic options and clinical trial opportunities that might otherwise remain undiscovered. Monetization for Tempus hinges on its relationships with various stakeholders in the healthcare ecosystem. It primarily earns revenue through partnerships with pharmaceutical companies, where it assists in drug discovery and development by offering detailed genomic data and analytics. Moreover, Tempus collaborates with research institutes and healthcare providers who rely on its AI-driven platform to enhance clinical decision-making and improve treatment outcomes. By bridging the gap between vast datasets and intricate patient care solutions, Tempus not only facilitates better healthcare practices but also solidifies its role as a vital link in the evolving landscape of modern medicine.

TEM Intrinsic Value
23.45 USD
Overvaluation 33%
Intrinsic Value
Price
T

See Also

What is Tempus AI Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
0 USD

Based on the financial report for Dec 31, 2023, Tempus AI Inc's Current Portion of Long-Term Debt amounts to 0 USD.

Back to Top